NOX-A12 (olaptesed pegol)
Glioblastoma (newly diagnosed, unmethylated MGMT)
Phase 2Active
Key Facts
Indication
Glioblastoma (newly diagnosed, unmethylated MGMT)
Phase
Phase 2
Status
Active
Company
About TME Pharma
TME Pharma is a Berlin-based, publicly traded biotech advancing a novel approach to cancer treatment by targeting the tumor microenvironment. Its lead asset, NOX-A12, is a CXCL12-neutralizing Spiegelmer in Phase 2 development for glioblastoma, showing promising survival data in combination regimens. The company is pre-revenue, with a financial runway extending beyond 12 months as of early 2026, and faces the critical challenges of advancing late-stage trials and securing additional funding or partnerships.
View full company profile